{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A217", "status": "success", "status_code": 200, "timestamp_elapsed": 0.009661, "timestamp_received": "2026-09-25T01:16:35.439944+00:00Z", "timestamp_returned": "2026-09-25T01:16:35.449605+00:00Z", "trace_id": "08017e86-8f8b-4d46-866c-c661cfbdf23f" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:rydapt:0:9", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2017-04-28:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2017-04-28", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:rydapt", "type": "Document", "documentType": "Regulatory approval", "name": "Rydapt (midostaurin) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Rydapt", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "midostaurin", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 207997, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2023-05-22", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:217", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:AML", "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML" ] } }, "objectTherapeutic": { "id": "txgrp:40", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C408", "conceptType": "Therapy", "name": "Cytarabine", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:3041", "code": "3041", "name": "cytarabine", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3041" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1311078", "code": "1311078", "name": "cytarabine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1311078" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:387511003", "code": "387511003", "name": "Cytarabine", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387511003&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4306038", "code": "4306038", "name": "Cytarabine", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4306038" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "DNA Polymerase inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408" ] } }, { "id": "tx:ncit:C62091", "conceptType": "Therapy", "name": "Daunorubicin", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:3109", "code": "3109", "name": "daunorubicin", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3109" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1311799", "code": "1311799", "name": "daunorubicin", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1311799" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:372715008", "code": "372715008", "name": "Daunorubicin", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=372715008&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4156866", "code": "4156866", "name": "Daunorubicin", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4156866" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Topoisomerase inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C62091", "code": "C62091", "name": "Daunorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091" ] } }, { "id": "tx:ncit:C1872", "conceptType": "Therapy", "name": "Midostaurin", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1919083", "code": "1919083", "name": "midostaurin", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1919083" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1594003", "code": "1594003", "name": "midostaurin", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1594003" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:763613005", "code": "763613005", "name": "Midostaurin", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=763613005&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:35622245", "code": "35622245", "name": "Midostaurin", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/35622245" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "FLT3 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1872", "code": "C1872", "name": "Midostaurin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:125", "present": true, "subject": { "id": "bmkr:125", "type": "CategoricalVariant", "name": "CDK12 oncogenic variants", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.v6dDopUoppRYaxKGZdqVJHBVgbRVIWIo", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_057591.2, the protein product of the MANE Select coding transcript for CDK12 (refseq:NM_016507.4).", "digest": "v6dDopUoppRYaxKGZdqVJHBVgbRVIWIo", "sequenceReference": { "id": "ga4gh:SQ.PAx2759Yy_waBKMXobh8lS9Z9Mbnr7l9", "type": "SequenceReference", "name": "NP_057591.2", "aliases": [ "ensembl:ENSP00000398880.3", "ga4gh:SQ.PAx2759Yy_waBKMXobh8lS9Z9Mbnr7l9", "refseq:NP_057591.2" ], "description": "The protein product of the MANE Select coding transcript for CDK12 (refseq:NM_016507.4), corresponding to the Refseq protein accession NP_057591.2.", "moleculeType": "protein", "refgetAccession": "SQ.PAx2759Yy_waBKMXobh8lS9Z9Mbnr7l9", "residueAlphabet": "aa" }, "start": 0, "end": 1490, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:24224", "conceptType": "Gene", "name": "CDK12", "primaryCoding": { "id": "coding:hgnc:24224", "code": "HGNC:24224", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000167258", "code": "ENSG00000167258", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000167258" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:51755", "code": "51755", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/51755" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_016507.4", "code": "NM_016507.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "17" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": null }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:rydapt:0", "type": "Indication", "description": "RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2017-04-28:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2017-04-28", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:rydapt", "type": "Document", "documentType": "Regulatory approval", "name": "Rydapt (midostaurin) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Rydapt", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "midostaurin", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 207997, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2023-05-22", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }